Trial Profile

Expanded Access Program With Oral Berotralstat for the Prevention of Attacks in Patients With Hereditary Angioedema

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Berotralstat (Primary)
Indications Hereditary angioedema
Focus Expanded access; Therapeutic Use
Sponsors BioCryst Pharmaceuticals

Most Recent Events

12 Jun 2020 New trial record
09 Jun 2020 According to an BioCryst Pharmaceuticals media release, the company has established an expanded access program (EAP) with oral, once-daily berotralstat, an investigational drug, for patients with hereditary angioedema (HAE) in the United States. Through this program, physicians may be able to request berotralstat for HAE patients who do not have access to the product through a clinical trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com